3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists
Graphical abstract
The design, synthesis, and structure–activity relationship (SAR) for a series of β-substituted 3-(4-aryloxy)propanoic acid GPR40 agonists is described. Systematic replacement of the pendant aryloxy group led to identification of potent GPR40 agonists. In order to identify candidates suitable for in vivo validation of the target, serum shifted potency and pharmacokinetic properties were determined for several compounds. Finally, further profiling of compound 7 is presented, including demonstration of enhanced glucose tolerance in an in vivo mouse model.
Section snippets
Acknowledgment
The authors thank Eric Cline for the preparation of compound 3.
References and notes (15)
- et al.
Bioorg. Med. Chem. Lett.
(2010)et al.Diabetes
(2008) - For other examples of β-substituted propionic acid GPR40 agonists...(a)Ackerman, M.; Houze, J.; Lin, D. C. H.; Liu, J.; Liu, J.; Luo, J.; Ma, Z.; Medina, J. C.; Qiu, W.; Reagan, J. D.;...(b)Ackerman, M.; Brown, S.; Houze, J.; Liu, J.; Liu, J.; Ma, Z.; Medina, J. C.; Qiu, W.; Schmitt, M. J.; Sharma, R.;...(c)Ackerman, M.; Houze, J.; Lin, D. C. H.; Liu, J.; Luo, J.; Medina, J. C.; Qiu, W.; Reagan, J. D.; Sharma, R.;...
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2011 Elsevier Ltd. All rights reserved.